- Home
- RLYB vs OTLK Comparison
RLYB vs OTLK Comparison
Compare RLYB & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLYB | OTLK |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7M | 29.2M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | RLYB | OTLK |
|---|---|---|
| Price | $8.67 | $0.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 263.8K | ★ 1.1M |
| Earning Date | 05-07-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | N/A | ★ N/A |
| Revenue | $858,000.00 | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,606.43 |
| Revenue Next Year | N/A | $93.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.00 | N/A |
| 52 Week Low | $0.22 | $0.29 |
| 52 Week High | $11.49 | $3.39 |
Technical Indicators
Market Signals| Indicator | RLYB | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 57.69 | 23.64 |
| Support Level | $0.48 | N/A |
| Resistance Level | $11.49 | $0.46 |
| Average True Range (ATR) | 0.69 | 0.04 |
| MACD | -0.41 | -0.01 |
| Stochastic Oscillator | 0.38 | 11.15 |
Price Performance
Historical ComparisonAbout RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.